Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SCRI-CAR22v2 |
Synonyms | |
Therapy Description |
SCRI-CAR22v2 cells are T-cells engineered to express a chimeric antigen receptor (CAR) that targets CD22, which may potentially inhibit growth of CD22-expressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SCRI-CAR22v2 | SCRI-CAR22v|SCRICAR22v2 | CD22 Immune Cell Therapy 15 | SCRI-CAR22v2 cells are T-cells engineered to express a chimeric antigen receptor (CAR) that targets CD22, which may potentially inhibit growth of CD22-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04571138 | Phase Ib/II | SCRI-CAR22v2 | A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma | Recruiting | USA | 0 |